Chromosome losses in tumorigenic revertants of EJ/ras-expressing somatic cell hybrids

Carol I. Pratt, Shi Qi Wu, Manju Bhattacharya, Chinghai Kao, Kennedy W. Gilchrist, Catherine A. Reznikoff

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Tumorigenic transformation of SV40-immortalized human uroepithelial cells (SV-HUC) after transfection with EJ/ras was previously reported to be a rare event. To test the hypothesis that ras transformation requires loss of suppressor genes, somatic cell hybrids were generated between a rare tumorigenic transformant and an isogeneic nontumorigenic EJ/ras transfectant obtained in the same experiment. Both parental cell lines, as well as all hybrid progeny, expressed mutant p21 ras protein, but injections of three such independent hybrids into athymic nude mice at passage (P) 4 demonstrated that tumorigenicity was suppressed at 20 of 22 sites. Two tumors developed, after a relatively long 17-week latent period, as compared with a 4-week latent period for the tumorigenic parent. All three hybrids produced tumors at P8, but these showed different latent periods (3-14 weeks). Revertant hybrid tumors were high-grade carcinomas. Cell lines derived from these tumors expressed mutant p21 ras and retained at least 1 EJ/ras integration site. Karyotypic analysis of six independent hybrid tumor revertants showed that each had a unique clonal karyotype. Losses of two or more homologues of 1p, 3p, 4, 8, 10p, 11p, 13q, and 18 were identified in one or more tumorigenic revertants. Losses of all these chromosomes were previously associated with transformation of SV-HUC by EJ/ras, but were also associated with chemical transformation of SV-HUC in tumors that did not express mutant ras. Genetic losses involving most of these chromosomes have also been identified in clinical bladder cancers (i.e., 1p, 3p, 8, 11p, 13 and 18q). These data show that expression of EJ/ras does not negate or significantly alter requirements for multiple genetic losses in HUC tumorigenesis.

Original languageEnglish (US)
Pages (from-to)180-190
Number of pages11
JournalCancer Genetics and Cytogenetics
Volume59
Issue number2
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Hybrid Cells
Chromosomes
Proto-Oncogene Proteins p21(ras)
Neoplasms
Nude Mice
Neoplastic Cell Transformation
Suppressor Genes
ras Proteins
Tumor Cell Line
Karyotype
Urinary Bladder Neoplasms
Transfection
Carcinogenesis
Carcinoma
Cell Line
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Chromosome losses in tumorigenic revertants of EJ/ras-expressing somatic cell hybrids. / Pratt, Carol I.; Wu, Shi Qi; Bhattacharya, Manju; Kao, Chinghai; Gilchrist, Kennedy W.; Reznikoff, Catherine A.

In: Cancer Genetics and Cytogenetics, Vol. 59, No. 2, 1992, p. 180-190.

Research output: Contribution to journalArticle

Pratt, Carol I. ; Wu, Shi Qi ; Bhattacharya, Manju ; Kao, Chinghai ; Gilchrist, Kennedy W. ; Reznikoff, Catherine A. / Chromosome losses in tumorigenic revertants of EJ/ras-expressing somatic cell hybrids. In: Cancer Genetics and Cytogenetics. 1992 ; Vol. 59, No. 2. pp. 180-190.
@article{f38769bae9a54ffb9d8398d30b51bb2a,
title = "Chromosome losses in tumorigenic revertants of EJ/ras-expressing somatic cell hybrids",
abstract = "Tumorigenic transformation of SV40-immortalized human uroepithelial cells (SV-HUC) after transfection with EJ/ras was previously reported to be a rare event. To test the hypothesis that ras transformation requires loss of suppressor genes, somatic cell hybrids were generated between a rare tumorigenic transformant and an isogeneic nontumorigenic EJ/ras transfectant obtained in the same experiment. Both parental cell lines, as well as all hybrid progeny, expressed mutant p21 ras protein, but injections of three such independent hybrids into athymic nude mice at passage (P) 4 demonstrated that tumorigenicity was suppressed at 20 of 22 sites. Two tumors developed, after a relatively long 17-week latent period, as compared with a 4-week latent period for the tumorigenic parent. All three hybrids produced tumors at P8, but these showed different latent periods (3-14 weeks). Revertant hybrid tumors were high-grade carcinomas. Cell lines derived from these tumors expressed mutant p21 ras and retained at least 1 EJ/ras integration site. Karyotypic analysis of six independent hybrid tumor revertants showed that each had a unique clonal karyotype. Losses of two or more homologues of 1p, 3p, 4, 8, 10p, 11p, 13q, and 18 were identified in one or more tumorigenic revertants. Losses of all these chromosomes were previously associated with transformation of SV-HUC by EJ/ras, but were also associated with chemical transformation of SV-HUC in tumors that did not express mutant ras. Genetic losses involving most of these chromosomes have also been identified in clinical bladder cancers (i.e., 1p, 3p, 8, 11p, 13 and 18q). These data show that expression of EJ/ras does not negate or significantly alter requirements for multiple genetic losses in HUC tumorigenesis.",
author = "Pratt, {Carol I.} and Wu, {Shi Qi} and Manju Bhattacharya and Chinghai Kao and Gilchrist, {Kennedy W.} and Reznikoff, {Catherine A.}",
year = "1992",
doi = "10.1016/0165-4608(92)90213-R",
language = "English (US)",
volume = "59",
pages = "180--190",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Chromosome losses in tumorigenic revertants of EJ/ras-expressing somatic cell hybrids

AU - Pratt, Carol I.

AU - Wu, Shi Qi

AU - Bhattacharya, Manju

AU - Kao, Chinghai

AU - Gilchrist, Kennedy W.

AU - Reznikoff, Catherine A.

PY - 1992

Y1 - 1992

N2 - Tumorigenic transformation of SV40-immortalized human uroepithelial cells (SV-HUC) after transfection with EJ/ras was previously reported to be a rare event. To test the hypothesis that ras transformation requires loss of suppressor genes, somatic cell hybrids were generated between a rare tumorigenic transformant and an isogeneic nontumorigenic EJ/ras transfectant obtained in the same experiment. Both parental cell lines, as well as all hybrid progeny, expressed mutant p21 ras protein, but injections of three such independent hybrids into athymic nude mice at passage (P) 4 demonstrated that tumorigenicity was suppressed at 20 of 22 sites. Two tumors developed, after a relatively long 17-week latent period, as compared with a 4-week latent period for the tumorigenic parent. All three hybrids produced tumors at P8, but these showed different latent periods (3-14 weeks). Revertant hybrid tumors were high-grade carcinomas. Cell lines derived from these tumors expressed mutant p21 ras and retained at least 1 EJ/ras integration site. Karyotypic analysis of six independent hybrid tumor revertants showed that each had a unique clonal karyotype. Losses of two or more homologues of 1p, 3p, 4, 8, 10p, 11p, 13q, and 18 were identified in one or more tumorigenic revertants. Losses of all these chromosomes were previously associated with transformation of SV-HUC by EJ/ras, but were also associated with chemical transformation of SV-HUC in tumors that did not express mutant ras. Genetic losses involving most of these chromosomes have also been identified in clinical bladder cancers (i.e., 1p, 3p, 8, 11p, 13 and 18q). These data show that expression of EJ/ras does not negate or significantly alter requirements for multiple genetic losses in HUC tumorigenesis.

AB - Tumorigenic transformation of SV40-immortalized human uroepithelial cells (SV-HUC) after transfection with EJ/ras was previously reported to be a rare event. To test the hypothesis that ras transformation requires loss of suppressor genes, somatic cell hybrids were generated between a rare tumorigenic transformant and an isogeneic nontumorigenic EJ/ras transfectant obtained in the same experiment. Both parental cell lines, as well as all hybrid progeny, expressed mutant p21 ras protein, but injections of three such independent hybrids into athymic nude mice at passage (P) 4 demonstrated that tumorigenicity was suppressed at 20 of 22 sites. Two tumors developed, after a relatively long 17-week latent period, as compared with a 4-week latent period for the tumorigenic parent. All three hybrids produced tumors at P8, but these showed different latent periods (3-14 weeks). Revertant hybrid tumors were high-grade carcinomas. Cell lines derived from these tumors expressed mutant p21 ras and retained at least 1 EJ/ras integration site. Karyotypic analysis of six independent hybrid tumor revertants showed that each had a unique clonal karyotype. Losses of two or more homologues of 1p, 3p, 4, 8, 10p, 11p, 13q, and 18 were identified in one or more tumorigenic revertants. Losses of all these chromosomes were previously associated with transformation of SV-HUC by EJ/ras, but were also associated with chemical transformation of SV-HUC in tumors that did not express mutant ras. Genetic losses involving most of these chromosomes have also been identified in clinical bladder cancers (i.e., 1p, 3p, 8, 11p, 13 and 18q). These data show that expression of EJ/ras does not negate or significantly alter requirements for multiple genetic losses in HUC tumorigenesis.

UR - http://www.scopus.com/inward/record.url?scp=0026762315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026762315&partnerID=8YFLogxK

U2 - 10.1016/0165-4608(92)90213-R

DO - 10.1016/0165-4608(92)90213-R

M3 - Article

C2 - 1316224

AN - SCOPUS:0026762315

VL - 59

SP - 180

EP - 190

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 2

ER -